Home » HEALTH RETURNING TO DRUG SECTOR, SAYS S&P
HEALTH RETURNING TO DRUG SECTOR, SAYS S&P
Standard & Poor's Equity Research Services, a leading provider of independent
investment analysis and research opinions, forecasts pharmaceutical profits
to rise modestly this year, helped by improved new products flows, Medicare
Part D, continued cost streamlining and a rosier picture for litigation issues.
Based on these improving conditions, Standard & Poor's raised its fundamental
outlook for large pharmaceutical firms to positive from neutral last week.
Drug Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May